Document Detail

Long-term disease stabilization in a patient with castration-resistant metastatic prostate cancer by the addition of lenalidomide to low-dose dexamethasone and celecoxib.
MedLine Citation:
PMID:  22868509     Owner:  NLM     Status:  In-Data-Review    
Background: Treatment of castrationresistant prostate cancer (CRPC) remains a challenge considering that most patients are elderly men with significant comorbidities. Alternative treatment strategies to cytotoxic therapy should be explored. There is evidence that the continuous administration of cyclooxygenase 2 (COX2) inhibitors and the immunomodulatory agents thalidomide or lenalidomide can result in longterm disease stabilization. Case Report: A 70-year-old patient with castrationresistant metastatic prostate cancer was treated with a combination of lowdose dexamethasone, celecoxib and subsequently lenalidomide. The patient had longterm disease stabilization for 33 months and a very good performance status despite moderate side effects, i.e. moderate Cushing's syndrome and mild laboratory hematologic toxicity. Conclusion: The addition of lenalidomide to low-dose dexamethasone and celecoxib resulted in an impressive longterm disease stabilization of CRPC in this patient, allowing him to lead an active life with a good quality of life.
Norbert Marschner; Matthias Zaiss
Related Documents :
24853389 - Alk-positive non-small cell lung cancer: mechanisms of resistance and emerging treatmen...
22790989 - The new era of staging as a key for an appropriate treatment for esophageal cancer.
22632109 - A randomised trial of robotic and open prostatectomy in men with localised prostate can...
22400019 - Radical prostatectomy and intraoperative radiation therapy in high-risk prostate cancer.
24073369 - Trial watch: immunostimulatory cytokines.
10070799 - Experimental validation of arthroscopic cartilage stiffness measurement using enzymatic...
9771449 - A prospective controlled study of the association of streptococcus bovis with colorecta...
17785559 - Overexpression of flipl is an independent marker of poor prognosis in colorectal cancer...
20869139 - Phenylmethylene hydantoins as prostate cancer invasion and migration inhibitors. comfa ...
Publication Detail:
Type:  Journal Article     Date:  2012-04-24
Journal Detail:
Title:  Onkologie     Volume:  35     ISSN:  1423-0240     ISO Abbreviation:  Onkologie     Publication Date:  2012  
Date Detail:
Created Date:  2012-08-07     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7808556     Medline TA:  Onkologie     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  279-82     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 S. Karger AG, Basel.
Praxis für Interdisziplinäre Onkologie und Hämatologie, Freiburg i.Br., Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Successful treatment of mediastinal seminoma in a hemodialysis patient.
Next Document:  Favorable response of heavily treated wilms' tumor to Paclitaxel and Carboplatin.